ya true but you know with the ohm list of 90 potential treatments for leronlimab and where our current sub dollar price is a buyout would make more sense for a big spending bp cos.imagine gilead pays $21 billion to get their hands on trodelvy immu but leronlimab is a way bigger bang for the buck. just a theory a partnership
works too for me.